Uterine Fibroid Embolization Device Market Size, Share & Trends Analysis Report By Product | Forecast to 2029
Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.
What Are The Future Growth Projections For The Uterine Fibroid Embolization Device Market Size?
In recent times, there has been a consistent expansion in the market size of the uterine fibroid embolization device. The progression will see the market rise from $5.62 billion in 2024 to $5.89 billion in 2025, representing a compound annual growth rate (CAGR) of 4.7%. Factors contributing to this growth during the historic period include a rising incidence of uterine fibroids, an inclination towards non-surgical alternatives, initiatives aimed at spreading awareness and education, attention on women’s health, a transition in favor of outpatient procedures, as well as training programs for physicians.
It is predicted that the market size for uterine fibroid embolization devices will witness a consistent expansion in the upcoming years, reaching $6.96 billion by 2029 at a compound annual growth rate (CAGR) of 4.3%. This growth during the projected period could be due to the rising awareness of non-invasive therapies, worldwide improvement of healthcare facilities, increasing commitment to female healthcare, the inclusion of a multidisciplinary approach to care, and the extension of outpatient services. Key trends expected for the forecast period consist of growing adoption of minimally invasive techniques, progressive advancements in embolic agents, tailor-made treatment strategies, a concentrated emphasis on outpatient ufe procedures, the integration of imaging technologies, and ongoing research into bioresorbable embolic agents.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13551&type=smp
Which Factors Are Steering Growth In The Uterine Fibroid Embolization Device Market?
The escalating preference for minimally invasive surgical procedures is anticipated to catalyze the expansion of the market for uterine fibroid embolization devices. Minimally invasive procedures are those defined by their utilization of tiny incisions or natural body orifices to access and treat internal biological structures with the goal of reducing patient trauma. Essential to these procedures are uterine fibroid embolization devices, crucial implements designed with precision to limit invasiveness by making the smallest incisions possible, mitigating the effect on adjacent tissues. As the demand for less invasive methodologies in medicine grows, these devices are now playing a pivotal role in enhancing patient outcomes. To illustrate, The Aesthetic Society, focused on plastic surgery and cosmetic medicine in the United States, reported in August 2023 that Americans spent over $11.8 billion on aesthetic procedures, a 2% increase from the last year. Thus, the surging preference for minimally invasive operations contributes immensely to the expansion of the uterine fibroid embolization device market.
How Is The Uterine Fibroid Embolization Device Market Organized By Different Segments?
The uterine fibroid embolization devicemarket covered in this report is segmented –
1) By Technology: Surgical Techniques, Laparoscopic Techniques, Ablation Techniques, Embolization Techniques
2) By Mode Of Treatment: Invasive Treatment, Minimally Invasive Treatment, Non-Invasive Treatment
3) By End User: Hospitals, Clinics, Ambulatory Surgical Center
Subsegments:
1) By Surgical Techniques: Open Surgery, Myomectomy
2) By Laparoscopic Techniques: Laparoscopic Myomectomy, Laparoscopic Hysterectomy
3) By Ablation Techniques: Radiofrequency Ablation, Microwave Ablation, Cryoablation
4) By Embolization Techniques: Transcatheter Arterial Embolization (TAE), Uterine Artery Embolization (UAE)
What Current And Upcoming Trends Are Shaping The Uterine Fibroid Embolization Device Market?
Prominent players in the uterine fibroid embolization device market are introducing advanced products such as the TruClear system in response to an increasing demand for less invasive uterine fibroid treatments, thereby enhancing both the safety and effectiveness of such methods. The TruClear system, a mechanical hysteroscopic tissue removal mechanism, is designed for treating intrauterine abnormalities (IUA) by offering a flexible catheter that is implanted into the uterus via the cervix. In November 2022, Medtronic Private Limited, a leading India-based medical equipment firm, debuted the new TruClear system. This system, designed to handle IUA, offers a secure and efficient solution to IUA treatment. With embedded features like a compact, flexible catheter, a revolving nitinol wire loop, uninterrupted inflow and outflow, in-built suction, and high-definition imaging, it makes uterine fibroid therapy more precise and secure.
Who Are The Most Influential Companies In The Uterine Fibroid Embolization Device Market?
Major companies operating in the uterine fibroid embolization device market report are Johnson and Johnson Pvt Ltd., Abbott Laboratories, Medtronic plc., Siemens Healthineers Ltd., Koninklijke Philips N.V., Stryker Corporation, Boston Scientific Corporation, GE HealthCare Technologies Inc., Olympus Corporation, Terumo Corporation, Smith and Nephew plc., Ethicon Inc., Hologic Inc., CooperSurgical Inc., Ferring B.V., Cook Medical Inc., Karl Storz GmbH, Merit Medical Systems, CONMED Corporation, Amsino International Inc., Lumenis Ltd., Richard Wolf GmbH, BTG International Ltd., Healthium MedTech Pvt. Ltd., INSIGHTEC Ltd., Hironic Co.Ltd., Minerva Surgical Inc., Gynesonics Inc., Advanced Surgical Concepts PLLC, Hitachi Medical Corporation
Access The Complete Report Here:
Which Region Dominates The Uterine Fibroid Embolization Device Market Today?
North America was the largest region in the uterine fibroid embolization device market in 2024. The regions covered in the uterine fibroid embolization device market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=13551&type=smp
Browse Through More Reports Similar to the Global Uterine Fibroid Embolization Device Market 2025, By The Business Research Company
Immunochemistry Diagnostic Devices And Equipment Global Market Report 2025
Implantable Drug Delivery Devices Global Market Report 2025
Interventional Cardiology Devices And Equipment Global Market Report 2025
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
